Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Express Scripts
McKesson
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,175,264

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,175,264
Title:Postnatal stem cells and uses thereof
Abstract: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.
Inventor(s): Shi; Songtao (Irvine, CA), Robey; Pamela Gehron (Bethesda, MD), Gronthos; Stan (Colonel Light Gardens, AU), Miura; Masako (Kyoto, JP)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC)
Application Number:10/553,633
Patent Claims:1. An isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells, wherein the human postnatal deciduous dental pulp multipotent stem cells are from a postnatal deciduous tooth; human postnatal deciduous dental pulp multipotent stem cells in the clonal population differentiate into a neural cell, an adipocyte, or an odontoblast; human postnatal deciduous dental pulp multipotent stem cells in the clonal population can proliferate to over 140 population doublings; and the isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells was expanded ex vivo, wherein the human postnatal deciduous dental pulp multipotent stem cells in the population express CD146.

2. The isolated clonal population of human postnatal deciduous stem cells of claim 1, wherein human postnatal deciduous stem cells within the population induce formation of a significant amount of bone, but do not form bone, when transplanted in vivo.

3. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein human postnatal deciduous dental pulp multipotent stem cells within the population express STRO 1.

4. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein human postnatal deciduous dental pulp multipotent stem cells within the population generate dentin when transplanted in vivo.

5. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein the human postnatal deciduous dental pulp multipotent stem cells are transfected with an exogenous nucleic acid segment that encodes a heterologous product, and wherein the cells express the product.

6. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein the postnatal deciduous tooth is an incisor.

7. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, obtained by the process of: separating pulp from a remnant crown of a human postnatal deciduous tooth; digesting the pulp in collagenase and dispase to form digested pulp; producing a single cell suspension from the digested pulp; and isolating single cells that adhere to a tissue culture surface from the single cell suspension and culturing the single cells in vitro.

8. An isolated human postnatal deciduous dental pulp multipotent stem cell as deposited with the American Type Culture Collection (ATCC) as PTA-11551, wherein the stem cell induces the formation of bone when transplanted in vivo.

9. A clonal cell isolated from the isolated population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein the clonal cell expresses neural markers when transplanted into the dentate hippocampus of an immunocompromised mouse in vivo.

10. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, wherein human postnatal deciduous dental pulp multipotent stem cells within the population do not express STRO-1.

11. A composition comprising a carrier and the cells deposited with the American Type Culture Collection (ATCC) as PTA-11551, wherein the composition induces the formation of bone when transplanted in vivo.

12. The composition of claim 11, consisting of the carrier, a medium, and the cells deposited with the American Type Culture Collection (ATCC) as PTA-11551, wherein the composition induces the formation of bone when transplanted in vivo.

13. A composition comprising a carrier and a mixed population of human postnatal deciduous dental pulp multipotent stem cells that have been cultured ex vivo, induce formation of bone growth when implanted in vivo, and can proliferate for over 140 population doublings, wherein the human postnatal deciduous dental pulp multipotent stem cells in the population express CD146, and a biocompatible three dimensional carrier.

14. The isolated clonal population of human postnatal deciduous stem cells of claim 1, wherein the isolated population is cryopreserved.

15. The isolated clonal population of human postnatal deciduous stem cells of claim 14, wherein the isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells is cryopreserved in liquid nitrogen.

16. A pharmaceutical composition comprising the isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 1, and a pharmaceutically acceptable carrier, wherein the human postnatal deciduous dental pulp multipotent stem cells survive in the carrier and wherein the pharmaceutical composition is sterile.

17. The pharmaceutical composition of claim 16, wherein the composition is a sterile implantable solution.

18. The composition of claim 13, wherein cells in the population have the capacity to differentiate into a neural cell, an adipocyte, or an odontoblast.

19. The composition of claim 13, wherein cells in the population express STRO-1.

20. The composition of claim 13, wherein cells in the population do not express STRO-1.

21. The isolated clonal population of human postnatal deciduous stem cells of claim 2, wherein human postnatal deciduous dental pulp multipotent stem cells within the population express ALP, matrix extracellular phosphoglycoprotein, basic fibroblast growth factor, endostatin, or any combination thereof when cultured in vitro.

22. The isolated clonal population of human postnatal deciduous stem cells of claim 10, wherein human postnatal deciduous dental pulp multipotent stem cells within the population express ALP, matrix extracellular phosphoglycoprotein, basic fibroblast growth factor, endostatin, or any combination thereof when cultured in vitro.

23. The composition of claim 13, wherein the biocompatible carrier is gelatin, a polyvinyl sponge, a collagen matrix, or a hydroxyapatite/tricalcuim phosphate ceramic.

24. The isolated clonal population of human postnatal deciduous dental pulp multipotent stem cells of claim 5, wherein the product is a growth factor, cytokine or chemokine.

Summary for Patent:   Start Trial

PCT Information
PCT FiledApril 19, 2003PCT Application Number:PCT/US03/12276
PCT Publication Date:November 04, 2004PCT Publication Number:WO2004/094588

Details for Patent 9,175,264

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,175,264

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Merck
Colorcon
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.